Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. cut its position in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 19.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,379 shares of the medical research company's stock after selling 2,539 shares during the quarter. Robeco Institutional Asset Management B.V.'s holdings in Laboratory Co. of America were worth $2,319,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LH. Van ECK Associates Corp boosted its stake in Laboratory Co. of America by 5.3% in the 3rd quarter. Van ECK Associates Corp now owns 13,868 shares of the medical research company's stock worth $3,050,000 after buying an additional 694 shares during the last quarter. White Pine Investment CO grew its holdings in Laboratory Co. of America by 1.6% in the third quarter. White Pine Investment CO now owns 19,078 shares of the medical research company's stock valued at $4,264,000 after purchasing an additional 309 shares during the period. Farther Finance Advisors LLC increased its position in Laboratory Co. of America by 17.7% during the third quarter. Farther Finance Advisors LLC now owns 1,385 shares of the medical research company's stock worth $310,000 after purchasing an additional 208 shares during the last quarter. Oak Harvest Investment Services purchased a new position in Laboratory Co. of America during the third quarter worth approximately $894,000. Finally, Lodestar Private Asset Management LLC acquired a new position in shares of Laboratory Co. of America in the 3rd quarter valued at $219,000. Institutional investors and hedge funds own 95.94% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on LH shares. Deutsche Bank Aktiengesellschaft upped their price objective on Laboratory Co. of America from $220.00 to $230.00 and gave the stock a "hold" rating in a report on Friday, August 2nd. Barclays raised their price target on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the company an "equal weight" rating in a report on Friday, October 25th. Jefferies Financial Group boosted their price objective on shares of Laboratory Co. of America from $245.00 to $265.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. Evercore ISI cut their target price on shares of Laboratory Co. of America from $250.00 to $240.00 and set an "in-line" rating on the stock in a research note on Tuesday, September 24th. Finally, Piper Sandler upped their price target on shares of Laboratory Co. of America from $235.00 to $240.00 and gave the stock a "neutral" rating in a research report on Monday, October 28th. Five investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $255.92.

Laboratory Co. of America Stock Up 1.4 %

Shares of Laboratory Co. of America stock traded up $3.34 on Friday, hitting $242.39. 854,652 shares of the company's stock traded hands, compared to its average volume of 657,143. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $243.78. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.66. The stock has a market cap of $20.27 billion, a P/E ratio of 46.88, a PEG ratio of 1.99 and a beta of 1.05. The firm's 50-day moving average is $223.02 and its 200 day moving average is $214.34.

Laboratory Co. of America (NYSE:LH - Get Free Report) last posted its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 EPS for the quarter, beating analysts' consensus estimates of $3.48 by $0.02. The firm had revenue of $3.28 billion for the quarter, compared to the consensus estimate of $3.26 billion. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The firm's revenue was up 7.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.38 EPS. Equities analysts anticipate that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Shareholders of record on Tuesday, November 26th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.19%. The ex-dividend date of this dividend is Tuesday, November 26th. Laboratory Co. of America's dividend payout ratio is presently 55.71%.

Insiders Place Their Bets

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the director now owns 13,722 shares of the company's stock, valued at $3,156,060. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, EVP Der Vaart Sandra D. Van sold 2,000 shares of the business's stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $227.05, for a total transaction of $454,100.00. Following the completion of the transaction, the executive vice president now owns 3,670 shares in the company, valued at $833,273.50. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Kerrii B. Anderson sold 1,000 shares of the stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the sale, the director now directly owns 13,722 shares in the company, valued at $3,156,060. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,000 shares of company stock valued at $4,043,950 in the last quarter. Insiders own 0.85% of the company's stock.

Laboratory Co. of America Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.